Cullinan Therapeutics, Inc. CGEM Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Cullinan Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s cash ratio?
- Cullinan Therapeutics, Inc. (CGEM) reported cash ratio of 2.1× in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s cash ratio changed year-over-year?
- Cullinan Therapeutics, Inc.'s cash ratio decreased by 23.8% year-over-year, from 2.8× to 2.1×.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s cash ratio has grown at a -27.6% compound annual growth rate (CAGR), from 11.7× to 2.3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.